MEDIA RELEASEAfqlir® (aflibercept) approved to treat various retinal diseases, including neovascular age-related macular degeneration (nAMD)One ...

Sandoz (SDZNY) said that the European Commission has granted marketing authorization for Afqlir (aflibercept) 2 mg vial kit and ...

Biosimilar aflibercept (P041) demonstrated comparable safety and efficacy to the originator aflibercept (Eylea) in treating patients with retinal conditions like neovascular age-related macular ...

BCVA improved +8.9 letters versus +3.2 letters for aflibercept control compared to baseline. CST improved 68.1 microns versus 30.5 microns for aflibercept control compared to baseline. Visual and ...

After the Federal Circuit’s denial last month of Regeneron’s motion for an injunction pending appeal, seeking to prevent Amgen from ...

Despite disappointing third-quarter results for Regeneron’s high-dose Eylea injection, analysts continued to be cautiously ...

The study comprised 161 patients split between three arms: EYP-1901 2mg (low dose; n=53); EYP-1901 3mg (high dose, n=54); and the standard of care, which was aflibercept 2mg every eight weeks (n=54).

Study points to approach to improving anti-VEGF therapy for all wet AMD patients, and help subset of patients who lose vision ...

In an interview with David Hutton of Ophthalmology Times, Ash Abbey, MD, discusses the Phase 3 LUGANO trial for EYP-1901 in treating wet age-related macular degeneration. Abbey discusses the trial’s ...

An intravitreal implant (OTX-TKI) containing the tyrosine kinase inhibitor axitinib (Inlyta) was well tolerated and significantly reduced injection frequency by nearly 90% in patients with wet ...

DURAVYU 2.7mg demonstrated an early, sustained, and clinically meaningful improvement in best-corrected visual acuity (BCVA) and anatomical control versus the aflibercept control arm. A favorable ...